SC
QNCX icon

Shay Capital’s Quince Therapeutics QNCX Stock Holding History

Shay Capital’s Portfolio QNCX Stock Details QNCX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$329K Buy
17,468
+8,603
+97% +$198K 0.02% 348
2026
Q1 		$180K Buy
+8,865
New +$1.78M 0.02% 397
2025
Q4 		– Sell
-685
Closed -$223K – 588
2025
Q3 		$223K Sell
685
-65
-9% -$21.6K 0.02% 344
2025
Q2 		$248K Sell
750
-172
-19% -$39.3K 0.03% 240
2025
Q1 		$245K Sell
922
-462
-33% -$141K 0.04% 219
2024
Q4 		$518K Buy
1,384
+523
+61% +$157K 0.08% 176
2024
Q3 		$134K Buy
+861
New +$123K 0.02% 267

Other funds holding QNCX

Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Shay Capital's QNCX Position: Q2 2026 in Review

Shay Capital increased its Quince Therapeutics (QNCX) stake by 97% in Q2 2026, buying an estimated $198K and bringing the position to 17,468 shares worth $329K. The position accounts for 0.02% of the portfolio, ranked #348.

Shay Capital first reported a position in QNCX in Q3 2024 and has held it in 7 quarters since. The position peaked at $518K in Q4 2024. 27 funds tracked by Wall St. Rank hold QNCX as of Q2 2026.

  • Shay Capital held 17,468 shares of Quince Therapeutics worth $329K as of Q2 2026.
  • Shay Capital bought 8,603 Quince Therapeutics shares in Q2 2026, an estimated $198K.
  • Quince Therapeutics made up 0.02% of Shay Capital's portfolio in Q2 2026, its #348 holding.
  • Shay Capital first reported a position in Quince Therapeutics in Q3 2024 and has held it in 7 quarters since.
  • Shay Capital's Quince Therapeutics position peaked at $518K in Q4 2024.
  • 27 funds tracked by Wall St. Rank held Quince Therapeutics as of Q2 2026.

Based on Shay Capital's 13F filing for Q2 2026, filed 14 Aug 2026.